Injection site was very sore/ the soreness was gone; expereinced swelling arround my injection area; Numbing, hand then becomes numb; Tingling effect; Pain started in hand; Pain; Pain is interfering with sleep; Pain in shoulder blade/left elbow; Discomfort in arm; Discomfort in neck, shoulder, back and hip; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.  Previously administered products included Shingles vaccine with an associated reaction of injection site pain (1st dose was received in 07 September 2022 in the left arm. and also had experienced Peripheral swelling. Kindly refer this case - US2023AMR045968) and Flu shot (was received in 07 September 2022 in the right arm.). Concurrent medical conditions included musculoskeletal discomfort (Discomfort in neck, shoulder, back and hip for about 60 days after the 1st vaccine was administered into his/her left arm) and arm discomfort (Discomfort in arm).  On 08-NOV-2022, the patient received the 2nd dose of Shingles vaccine (left arm). On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced injection site pain (Verbatim: Injection site was very sore/ the soreness was gone), peripheral swelling (Verbatim: expereinced swelling arround my injection area), numbness (Verbatim: Numbing, hand then becomes numb), tingling feet/hands (Verbatim: Tingling effect), pain in hand (Verbatim: Pain started in hand), pain (Verbatim: Pain), difficulty sleeping (Verbatim: Pain is interfering with sleep), shoulder pain (Verbatim: Pain in shoulder blade/left elbow), arm discomfort (Verbatim: Discomfort in arm) and neck discomfort (Verbatim: Discomfort in neck, shoulder, back and hip). The patient was treated with paracetamol (Tylenol). Rechallenge with Shingles vaccine was positive. The outcome of the injection site pain and peripheral swelling were resolved and the outcome of the numbness, tingling feet/hands, pain in hand, shoulder pain, arm discomfort and neck discomfort were not reported and the outcome of the pain and difficulty sleeping were not resolved.  It was unknown if the reporter considered the injection site pain, peripheral swelling, numbness, tingling feet/hands, pain in hand, pain, difficulty sleeping, shoulder pain, arm discomfort and neck discomfort to be related to Shingles vaccine.  It was unknown if the company considered the injection site pain, peripheral swelling, numbness, tingling feet/hands, pain in hand, pain, difficulty sleeping, shoulder pain, arm discomfort and neck discomfort to be related to Shingles vaccine.  Linked case(s) involving the same patient: US2023AMR045968  Additional Information: GSK Receipt Date: 05-MAY-2023 The patient had reported that he/she had received a form in the mail today (on the day of reporting) requesting information about a shingles vaccine that he/she had received 5 months ago and later experienced numbing and sharp pain in my left shoulder blade and it goes to his/her left elbow. His/Her left hand then become numb with the tingling effect and this happened whether he/she was relaxing and sleeping or while using his left hand. He/She had not seen the physician for this problem caused he/she does not had any extra funds to be used for a physician appointment. He/She had visited a nearby clinic for his/her shingles vaccinations. He/She had received the second dose of shingles vaccine in his/her left arm and experienced no discomfort.  But his/her left arm injection area was still sore and he/she had felt discomfort for about 60 days after the vaccine was administered into his/her left arm. The soreness was gone and then the pain started in his/her left shoulder blade, left elbow and hand. This letter explained that, what he/she had dealt with since his/her shingles dosages were given and was why he/she had contacted our company. He/She was not sure if the shingles vaccination had caused his/her arm discomfort. The reporter had consented to follow-up.; Sender's Comments:  US-GSK-US2023AMR045968:Same reporter